Anti-inflammatory product order boost for MGC
PERTH: Trailblazing bio-pharma company MGC Pharmaceuticals, who specialises in the development and production of phytocannabinoid-derived medicines, says it has received a much larger initial purchase order for its anti-inflammatory product, ArtemiC Rescue than first envisaged.
The order was placed by European nutraceutical producer and distributor, Swiss PharmaCan, or “SPC” and equates to an 85 per cent increase from the original contemplated purchase order. The revamped order will now tip the scales at $425,000.
ASX-listed MGC Pharma describes ArtemiC as a clinically tested food supplement containing four natural-based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata and Vitamin C. It says the expanded sale to SPC is part of an agreed quarterly minimum wholesale shipment of 40,000 units of the ArtemiC product line under the two companies’ exclusive master supply and distribution agreement, which is scheduled to run for a minimum of three years.
Last month’s signing of the agreement between SPC and MGC Pharma for the worldwide supply and distribution of ArtemiC Rescue as a food supplement follows the recent completion of the company’s Phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients.
The study was designed to evaluate the safety and efficacy of MGC’s anti-inflammatory product.
According to management, the key results of the trial on patients in Israel and India point to ArtemiC Rescue’s safety and efficacy with no adverse effects.
MGC Pharma says the results also underline the drug’s ability to prevent deterioration in the condition of COVID-19 patients and may lead to a faster clinical improvement and reduce symptoms and pain associated with COVID-19.
ArtemiC Rescue can now be produced in commercial-scale batches at MGC Pharma’s current manufacturing production facility in Slovenia.






